Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Total Debt (2021 - 2025)

Ascendis Pharma A's Total Debt history spans 3 years, with the latest figure at $677.9 million for Q4 2023.

  • For Q4 2023, Total Debt rose 34.35% year-over-year to $677.9 million; the TTM value through Dec 2023 reached $677.9 million, up 34.35%, while the annual FY2023 figure was $681.6 million, 30.75% up from the prior year.
  • Total Debt for Q4 2023 was $677.9 million at Ascendis Pharma A, up from $504.6 million in the prior quarter.
  • Across five years, Total Debt topped out at $677.9 million in Q4 2023 and bottomed at $120.1 million in Q4 2021.
  • The 3-year median for Total Debt is $504.6 million (2022), against an average of $434.2 million.
  • The largest annual shift saw Total Debt surged 320.25% in 2022 before it surged 34.35% in 2023.
  • A 3-year view of Total Debt shows it stood at $120.1 million in 2021, then soared by 320.25% to $504.6 million in 2022, then soared by 34.35% to $677.9 million in 2023.
  • Per Business Quant, the three most recent readings for ASND's Total Debt are $677.9 million (Q4 2023), $504.6 million (Q4 2022), and $120.1 million (Q4 2021).